Articles by Daniel Marsh
Moderna Drops 3.4% on $2.6B Convertible Offering Amid Cancer Vaccine Rally
Moderna shares slid 3.4% to $137.86 after pricing a $2.6B zero-coupon convertible notes offering, sparking dilution worries and cooling the recent cancer-vaccine rally.
Roivant Dips 2.7% Despite FDA Nod for LISRAYA; JPMorgan Sees $2B Peak Sales
Roivant shares slipped 2.7% to $36.58 despite FDA approval of LISRAYA, the first oral treatment for dermatomyositis. JPMorgan sees peak U.S. sales exceeding $2 billion.
Kazia Therapeutics Slides 7.3% on $40M Equity Offering After Clinical Rally
Kazia Therapeutics shares dropped 7.3% after pricing a $40 million equity offering, capitalizing on a recent clinical data surge but diluting existing shareholders.
BioLineRx Plunges 20% on Dilutive $3.75M Offering
BioLineRx shares dropped 20% after a $3.75M offering priced at $2.78 per ADS, with warrants that could significantly increase dilution.
Quoin Rockets 42% on QRX003 Data, Unveils $50M Funding Plan
Quoin shares jumped 41.8% after QRX003 met its primary endpoint in an interim analysis. The company also announced a $50 million fundraising.
Marvell Stock Slides 6.9% as Google AI Revenue Shift Delays Boost to 2029
Marvell shares dropped 6.9% premarket after Google's AI revenue timeline pushed significant gains to fiscal 2029, despite record Q2 revenue.
PayPal Plunges 15% as $53B Acquisition Talks Collapse
PayPal shares tumbled 15.4% after dropping a $53 billion acquisition attempt, wiping out $8.1 billion in market value and raising growth concerns.
Founder Group Slumps 23% Premarket on Second Reverse Split
Founder Group shares fell 22.7% in premarket trading after the company revealed a second 100-for-1 reverse stock split, its second in seven months, set to take effect September 1.
E-Power Soars 23% on Record $51.1M Anode Contract
E-Power shares surged 23% premarket after securing a $51.1 million anode-line contract, which exceeds its 2025 revenue. The project adds 21,000 tons of annual capacity.
Propanc Biopharma Plunges 19% Premarket After 108% Surge on PRP Data
Propanc Biopharma (PPCB) shares dropped 19.3% premarket to $1.80 after a 108% surge on PRP data. Despite strong animal results, revenue and cash concerns persist.
Solstice Surges 17% After Scrapping $14.5B Merger, Unveiling $500M Buyback
Solstice shares surged 17.2% in premarket trading after the company terminated its $14.5 billion merger with Element Solutions and announced a $500 million buyback.
LogProstyle Stock Retreats 30% Premarket After I-FLATZ Deal Rally
LogProstyle shares tumbled 30% in premarket trading, giving back gains from a 75% surge after announcing its I-FLATZ acquisition.